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Aims Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor

blockers (ARBs) prevent the progression of diabetic nephropathy (DN). Studies
suggest that combination renin–angiotensin–aldosterone system (RAAS)-inhibiting
therapy provides additive benefit in DN. However, these studies are small in size.
We performed a meta-analysis of studies investigating combination therapy for DN.
Methods Studies were identified through a search of

MEDLINE, EMBASE, CINAHL
and the Cochrane Database. All trials involving combined ACEI and ARB for
slowing progression of DN were included. The primary end point was 24-h
urinary protein excretion. Blood pressure, serum potassium and glomerular filtration rate (GFR) were secondary end points.

Results In the 10 included trials, 156 patients received ACEI + ARB and 159
received ACEI only. Most studies were 8–12 weeks in duration. Proteinuria was
reduced with ACEI + ARB (P = 0.01). This was associated with significant
statistical heterogeneity (P = 0.005). ACEI + ARB was associated with a reduction
in GFR [3.87 ml/min (7.32–0.42); P = 0.03] and a trend towards an increase in
serum creatinine (6.86 µmol/l 95% CI −0.76–13.73; P = 0.09). Potassium was
increased by 0.2 (0.08–0.32) mmol/l (P < 0.01) with ACEI + ARB. Systolic and
diastolic blood pressure were reduced by 5.2 (2.1–8.4) mmHg (P < 0.01) and
5.3 (2.2–8.4) mmHg (P < 0.01), respectively.
Conclusions This meta-analysis suggests that ACEI + ARB reduces 24-h pro-

teinuria to a greater extent than ACEI alone. This benefit is associated with small
effects on GFR, serum creatinine, potassium and blood pressure. These results
should be interpreted cautiously as most of the included studies were of short
duration and the few long-term studies (12 months) have not demonstrated benefit.
Diabet. Med. 24, 486–493 (2007)
Keywords angiotensin-converting enzyme inhibitor, angiotensin-receptor blocker,

combination therapy, diabetic nephropathy
Abbreviations ACEI, angiotensin-converting enzyme inhibitor; ARB, angtiotensin receptor blocker; DN, diabetic nephropathy; GFR, glomerular filtration
rate; RAAS, rennin–angiotensin–aldosterone system
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Diabetes mellitus currently affects 18.2 million Americans,
roughly 6.3% of the total population [1]. Diabetic nephropathy (DN) affects 10–21% of people with diabetes mellitus,
and is the leading cause of end-stage renal disease in the USA,
accounting for approximately 43% of new cases of end-stage
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renal disease [2]. DN is characterized by the development of
microalbuminuria, which, if left untreated, can lead to overt
proteinuria, a progressive decline in renal function, and eventually renal failure [3].
Randomized trials have consistently demonstrated the benefit of ACE inhibitors (ACEIs) [4–8] and angiotensin receptor
blockers (ARBs) [9–11] in slowing the progression of DN in
patients with both Type 1 and Type 2 diabetes mellitus. The
results of these trials are reflected in numerous guidelines.
For instance, the American Diabetes Association position
statement recommends an ACEI or an ARB for all patients
with microalbuminuria or advanced stages of nephropathy
[12]. The National Kidney Foundation guidelines on hypertension and anti-hypertensive agents in chronic kidney disease
recommend that patients with diabetic kidney disease, with or
without hypertension, should be treated with either an ACEI
or an ARB [13].
Although this body of literature clearly supports the use of
either an ACEI or an ARB, there is a growing interest in dual
blockade of the renin–angiotensin–aldosterone system (RAAS)
for the treatment of DN. The RESOLVD Pilot Study demonstrated that combining enalapril with candesartan provided
superior suppression of left-ventricular remodelling and RAAS
neurohormones than either therapy alone [14]. This trial demonstrates that single-drug therapy directed against the RAAS
results in incomplete blockade of this system, a phenomenon
commonly referred to as ‘ACE escape’. While the notion of
ACE escape provides a rationale for the combination of an
ACEI and an ARB in treating diseases associated with the
RAAS such as DN, the RESOLVD pilot study did not examine
this end point.
Several studies have examined the role of combined ACEI/
ARB therapy for DN [15–27]. Although these studies support
the benefit of combination therapy, all but one were small, involving only 24 patients or less. Therefore, less is known about the
role of dual RAAS blockade in patients with DN. The purpose
of this meta-analysis is to pool the results of these small studies
in order to better understand the role of dual angiotensin II
antagonism for the treatment of DN.

Methods
Identification and selection of studies

We conducted a search of MEDLINE (January 1966 to May
2006), EMBASE (1980 to May 2006) and CINAHL (1982 to May
2006) to identify all trials published in English involving the
combination of an ACEI and an ARB for treatment of DN. We
used the medical subject headings (including all subheadings)
and text keywords ‘ACE inhibitor and angiotensin receptor
blocker and combination and diabetic nephropathy’ as our
search parameters. In addition, we performed a manual search
of the literature using the references of original manuscripts
and review articles. Finally, a search of the Cochrane database
of systematic reviews was conducted. We included any randomized, controlled, parallel or crossover trial comparing an
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ACEI or an ARB to the combination of the two for the treatment of DN. Studies were also required to report 24-h urinary
protein excretion for inclusion.

Outcomes and statistical analysis

Summary results and selected characteristics of each clinical
trial were tabulated. The primary outcome analysed was the
comparative change in 24-h urinary protein excretion for an
ACEI alone or in combination with an ARB. When reported,
per cent reduction in protein excretion was also evaluated as
a secondary analysis. In addition, systolic blood pressure, diastolic blood pressure, serum creatinine, serum potassium and
glomerular filtration rate (GFR) were analysed in order to
assess the safety of dual blockade of the RAAS.
Weighted mean differences were calculated using RevMan
vs. 4.2.7 [28] utilizing a random effects model (DerSimonian
and Laird methodology). Statistical heterogeneity was assessed
with a χ2-test. Statistical heterogeneity is present when significant variability exists in the results of the studies included in the
meta-analysis. A P-value of < 0.1 defined significant heterogeneity. To assess the potential for publication bias, a funnel plot
analysis was also performed.
To establish the effect of clinical heterogeneity of the included studies on the results of the meta-analysis, subgroup analysis
was performed. The effect of study medication dose, type of
diabetes, change in systolic blood pressure and baseline level of
proteinuria were examined. Sensitivity analyses were conducted
to determine the robustness of our analysis. One of the analyses was conducted by excluding all non-randomized and
unblinded studies. The other excluded two studies with designs
that were dissimilar from the others in the analysis [23,25].

Results
Studies and patients

Ten studies were identified that met inclusion criteria (Table 1),
nine of which were crossover trials. Three studies were excluded
because 24-h urinary protein excretion was not reported [15,27,29].
Two other studies, one included and one excluded in this analysis, integrated both patients with diabetic and non-diabetic
nephropathy [21,26]. The study that was included presented
the results separately for the two different groups, allowing
extraction of only the data referring to the patients with diabetes for our analysis [21]. The other study was excluded because
the four patients without diabetes were not presented separately from those with diabetes [26]. A funnel plot suggested
that publication bias cannot be ruled out (data not shown).
The baseline characteristics of the patients analysed are presented in Table 1. Of the 159 patients in the final analysis, 156
were exposed to combination therapy and 159 were exposed
to the control (ACEI alone). Detailed exclusion criteria were
provided for five of the 10 studies and included contraindications to either an ACEI or an ARB, a serum potassium greater
than 4.6 mmol/l, a systolic blood pressure less than 100 mmHg,
or a glomerular filtration rate less than 30 ml/min. Baseline
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Population

Demographics

Combination

Control

Albumin excretion

Included?

Jacobsen et al. [18]

R, DB, PC, CO,
8 weeks in each
arm

Nineteen patients
with Type 1 DM,
HTN and proteinuria

Eighteen white
patients with
Type 1 DM and
proteinuria

Baseline: 701 ± 554
Control–Post: 239 ± 192
Combo–Post: 138 ± 127
P < 0.01

Yes

Jacobsen et al. [17]

R, DB, PC, CO,
8 weeks in each
arm

Twenty-four patients
with Type 1 DM
and proteinuria

Irbesartan 300 mg daily
+
enalapril 40 mg daily

Placebo
+
lisinopril 20 mg, enalapril
20 mg or captopril 100 mg
daily
Placebo
or
valsartan 80 mg daily
or
benazepril 20 mg daily
Placebo
+
enalapril 40 mg daily

Yes

R, DB, PC, CO,
8 weeks in
eacharm

Irbesartan 300 mg daily
+
lisinopril 20 mg, enalapril
20 mg or captopril 100 mg
daily
Valsartan 80 mg daily
+
benazepril 20 mg daily

Baseline: 1866 ± 934
Control–Post: 1574 ± 1079
Combo–Post: 996 ± 801
P < 0.001

Jacobsen et al. [16]

Baseline: NR
Control–Post: 519 ± 559
Combo–Post: 373 ± 497
P < 0.001

Yes

Rossing et al. [20]

R, DB, PC, CO,
8 weeks in each
arm

Seventeen patients
with Type 2 DM,
HTN and
proteinuria
Twenty white
patients with Type 2
DM, HTN and
proteinuria

Placebo
+
lisinopril 20 mg, enalapril
20 mg or captopril 100 mg
daily
Placebo
+
lisinopril 40 mg, enalapril
40 mg or captopril 150 mg
daily

Yes

R, DB, PC, CO,
8 weeks in each
arm

Candesartan 8 mg daily
+
lisinopril 20 mg, enalapril
20 mg or captopril 100 mg
daily
Candesartan 16 mg daily
+
lisinopril 40 mg, enalapril
40 mg or captopril 150 mg
daily

Baseline: 1764 ± 1383
Control–Post: 1764 ± 1383
Combo–Post: 1334 ± 1165
P = 0.036

Rossing et al. [19]

Age: 45 ± 10 years
Male: 81%
DM: 29 ± 8 years
DN: 10 ± 5 years
CCB: 48%
Age: 43 ± 7 years
Male: 72%
DM: 30 ± 7 years
DN: 10 ± 6 years
CCB: NR
Age: 42 ± 9 years
Male: 71%
DM: 31 ± 9 years
DN: 13 ± 5 years
CCB: 25%
Age: 58 ± 8 years
Male: 76%
DM: 13 ± 6 years
DN: 8 ± 5 years
CCB: 65%
Age: 62 ± 8 years
Male: 85%
DM: 15 ± 8 years
DN: NR
CCB: 65%

Yes

Kim et al. [21]

R, DB, PC, CO,
12 weeks in each
arm

Twenty-two patients
with Type 2 DM
and proteinuria

Candesartan 4 mg daily
+
rampril 5–7.5 mg daily

Placebo
+
rampril 5–7.5 mg daily

Baseline: NR
Control–Post: 706 ± 635
Combo–Post: 508 ± 617
P < 0.001
Baseline: 4000 ± 1400
Control–Post: 4100 ± 1407
Combo–Post: 3800 ± 938
P = NS

Kuriyama et al. [22]

CO, 12 weeks in
each arm

Nine patients
with Type 2 DM,
HTN, proteinuria
and CKD

Candesartan 4 mg daily
+
temocapril 2 mg daily

Temocapril 2 mg daily

Baseline: 4300 ± 1800
Control–Post: 3500 ± 1700
Combo–Post: 2600 ± 1300
P < 0.01

Yes

Age: 43 ± 19 years
Male: 59%
DM: NR
DN: NR
CCB: 88%
Age: 50 ± 10 years
Male: 44%
DM: NR
DN: NR
CCB: NR

Yes
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Table 1 Comparison of trials with combination RAAS therapy for diabetic nephropathy

Methods

Population

Demographics

Combination

Control

Albumin excretion

Included?

Hebert et al. [23]

CO, 1 week in
each arm

Seven patients
with Type 1 and
Type 2 DM and
proteinuria

Age: 59 ± 16 years
Male: 57%
DM: NR
DN: NR
CCB: 57%

Captopril 100–150 mg,
enalapril 10–20 mg,
lisinopril 10 mg or
fosinopril 20 mg daily

Baseline: 5970 ± 5580
Control–Post: 5300 ± 2100
Combo–Post: 5300 ± 2100
P = NR

Yes

Tutuncu et al. [25]

R, P, 12 months

Twenty-two patients
with Type 2 DM
and proteinuria

Age: 54 ± 7 years
DM: 8 ± 6 years
DN: NR
CCB: NR

Losartan 50–100 mg daily
+
captopril 100–150 mg,
enalapril 10–20 mg, lisinopril
10 mg or fosinopril 20 mg
daily
Losartan 50 mg daily
+
enalapril 5 mg daily

Losartan 50 mg daily
or
enalapril 5 mg daily

Yes

Cetinkaya et al. [24]

R, CO, 12 weeks
in each arm

Eleven patients
with HTN,
Type 2 DM and
proteinuria

Losartan 50 mg daily
+
enalapril 10 mg daily

Enalapril 10 mg daily

Morgensen et al. [15]

R, DB, P, 12 weeks

Candesartan 16 mg daily
+
lisinopril 20 mg daily
(67 patients)

No

R, PC, CO, 4 weeks
in each arm

Losartan 50 mg daily
+
lisinopril 40 mg daily

Candesartan 16 mg daily
(66 patients)
or
lisinopril 20 mg daily
(64 patients)
Placebo
+
lisinopril 40 mg daily

18% (−20% to +44%)
increase in urine albumin
-to-creatnine ratio
P > 0.2

Agarwal et al. [26]

Fujisawa et al. [27]

Observational,
12 weeks

One hundred and
ninety-nine patients
with HTN, Type 2
DM, and microproteinuria
Sixteen patients
with HTN,
proteinuria >
1 g/day (12 had
DM)
Twenty-seven
patients with
Type 2 DM

Candesartan 4 mg daily
+
imidapril 5 mg daily

Candesartan 8 mg daily
or
imidapril 10 mg daily

Andersen et al. [29]

R, DB, P,
12 months

Age: 54 ± 8 years
Male: 55%
DM: NR
DN: NR
CCB: NR
Age: 59.8 ± 9.2 years
Male: 65%
DM: 9.1 ± 7.5 years
DN: NR
CCB: NR
Age: 53 ± 9 years
Male: 88%
DM: NR
DN: NR
CCB: NR
Age: 62.4 ± 8.5 years
Male: 55%
DM: 14 ± 6.9 years
DN: NR
CCB: NR
Age: 54–56 ± 9 years
Male: 75%
DM: 11 years
DN: NR
CCB: 23%

Control–Pre: 85.0 ± 31.3
Control–Post: 35.4 ± 19.6
P = 0.0001
Combo–Pre: 102.0 ± 32.8
Combo–Post: 40.7 ± 29.5
P = 0.0003
Baseline: 4820 ± 1110
Control–Post: 3170 ± 690
Combo–Post: 2360 ± 400
P < 0.05

Lisinopril 20 mg daily
+
candesartan 16 mg daily

Lisinopril 40 mg daily

+1% (−20% to +28%)
increase in urine protein
excretion
P = 0.89
34% (14% to 49%)
reduction in urinary
albumin index
P = 0.003

No

BP, blood pressure; CCB, calcium channel blocker; CO, crossover; DB, double-blind; DM, diabetes mellitus; DN, diabetic nephropathy; HTN, hypertension; NR, not reported; P, parallel; PC, placebo
controlled; R, randomized.
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Seventy-five patients
with Type 1
or Type 2 DM
and HTN

Yes
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A final subgroup analysis evaluated the impact of blood
pressure reduction on proteinuria. In this analysis, mean
change in systolic blood pressure was used to divide the studies
into tertile subgroups. Change in proteinuria tended to be
most pronounced when larger reductions in blood pressure
were present and least pronounced when there was little or no
reduction in blood pressure (Fig. 2d).
Sensitivity analysis

FIGURE 1 This figure presents the overall results of the meta-analysis.
The black diamond represents the weighted mean difference and 95%
confidence interval. WMD, weighted mean difference. *Statistical
heterogeneity is demonstrated by P = 0.005. **Overall significance is
demonstrated by P = 0.01.

blood pressure was reported for eight of 10 studies, and of
these trials, populations in six of the eight were considered
hypertensive. Most studies were 8–12 weeks in duration.
Quantitative data analysis
Efficacy end point

The meta-analysis of 10 trials demonstrated a reduction in
24-h proteinuria (P = 0.01, Fig. 1); this reduction was associated with significant statistical heterogeneity between trials
(P < 0.005).
In the subgroup analysis of the effect of dose of medication
used in the various studies, we divided the studies into two
groups, those in which an ARB was added to maximal doses
of ACEI [17,19], and those in which an ARB was added to submaximal doses of an ACEI (Fig. 2a) [16,18,20–25]. There was
only a trend toward benefit in the maximal dose subgroup
(P = 0.17), while analysis of the eight studies using submaximal doses did demonstrate benefit (P = 0.03). Subgroup analysis in which patients with Type 1 [16–18] and Type 2 [19–25]
diabetes were analysed separately demonstrated a trend
favouring combination therapy for both Type 1 and Type 2
diabetes mellitus (P = 0.06 for both subgroups, Fig. 2b).
In order to explore the influence of baseline level of proteinuria, per cent reduction in protein excretion was analysed
(available for five of the included studies) [16–20]. In this analysis, there was an additional 39.4% (95% CI = 9.3–69.5%,
P = 0.010) reduction in protein excretion with combination
therapy. A subgroup analysis was also completed in an effort
to address this issue. In this analysis, baseline level of proteinuria was used to divide the studies into tertiles. The beneficial
effects of combination therapy appeared to decline as baseline
level of proteinuria declined (Fig. 2c).

490

Removal of non-randomized, unblinded studies from our
analysis did not alter the results for the primary end point significantly (P = 0.007); however, the heterogeneity was greatly
reduced (P = 0.67). Removal of the only study that did not
employ a crossover design [25] and the study that was only
1 week in duration [23] had little impact on the results
(P = 0.004). These results are presented in more detail in Fig. 2.
Safety end points

Analysis of the systolic and diastolic blood pressure for these
studies demonstrated a reduction in both parameters. The mean
change in systolic and diastolic blood pressure was −5.2 mmHg
(95% CI −8.4 to −2.1; P < 0.01) and −5.3 mmHg (95% CI −8.4
to −2.2; P < 0.01), respectively. Three studies were not included
in this analysis; two because the blood pressure was only
reported as mean arterial pressure, and another because blood
pressure data was not available for all patients [21,23,24].
Dual blockade of the RAAS was associated with a mean
decrease in GFR of 3.87 ml/min (95% CI 7.32–0.42; P = 0.03)
[16–22] with a trend towards an increase in serum creatinine
(6.86 µmol/l 95% CI −0.76–13.73; P = 0.09) [16–20,22–24].
Serum potassium was increased by a mean of 0.2 mmol/l (95%
CI 0.08–0.32; P < 0.01) with combination therapy [16–23].

Discussion
The pathophysiologic basis for dual blockade of the RAAS is
rooted in the multiple pathways in which angiotensin II and
aldosterone are generated. In addition to ACE, other enzymes
such as chymase can produce angiotensin II, suggesting incomplete blockade of the RAAS with ACEI or ARBs alone [14,30].
The ability of these two therapeutic agents to synergistically
antagonize the RAAS can also be explained by their complimentary mechanisms of action. For example, ACE inhibition
leads to a prolonged half-life of bradykinin, a potent vasodilator believed to be renoprotective [31]. ARBs do not increase
the half-life of bradykinin. They can further ablate the damaging effects resulting from the production of angiotensin II by
non-ACE pathways, which is not completely blocked by an
ACEI. Thus, it seems plausible that combining these two agents
could more effectively oppose the RAAS than either agent alone.
The results of this meta-analysis suggest that short-term
(i.e. most studies were 8–12 weeks in duration) combination
therapy with an ACEI and an ARB is superior to ACE inhibition
alone in reducing 24-h urinary protein excretion in patients
with DN. Given the paucity of studies longer than 12 weeks in
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FIGURE 2 Visual representation of subgroup and sensitivity analyses. Each line represents the weighted mean difference and 95% confidence interval
for the analysis. Lines crossing zero represent analyses in which there was no significant difference between combination therapy and ACE inhibitor
monotherapy. Lines falling completely to the left of zero represent analyses where combination therapy was superior. ACEI, Ace inhibitor;
CO, crossover; DB, double blind; R, randomized; SBP, systolic blood pressure; WMD, weighted mean difference (mg/24 h). *Mean (95% confidence
interval) reported for each tertile.

duration, this meta-analysis is not able to provide insight into
the effect of longer durations of dual RAAS blockade. Combination therapy resulted in a statistically and clinically significant decrease in GFR. This decrease may have been because of
the observed reductions in both systolic and diastolic blood
pressure, which could have resulted in diminished renal perfusion. The duration of the included studies was relatively
short; therefore, this decrease in GFR could also have been a
transient reduction. However, a decrease of nearly 4 ml/min
in GFR after only 2–3 months of dual therapy is somewhat
concerning and should be considered in assessing the risk/

© 2007 The Authors.
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benefit of this treatment strategy. There was also a statistically
significant increase in serum potassium with dual blockade of
the RAAS in our analysis. Although this increase was small and
is probably not clinically significant, it is still a potential disadvantage to this strategy, especially when one considers the
short duration of most of the included studies. It should be
noted that hyperkalaemia (K+ > 5.0 mmol/l) was only reported
in seven of the included patients [16–19,21].
The COOPERATE study determined the role of dual RAAS
blockade in slowing the progression of nephropathy in patients
without diabetes [32]. In this study, combination therapy with
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losartan and trandolapril resulted in an approximate 50%
reduction in the rate of doubling of serum creatinine or
development of end-stage renal disease over a 3-year period,
when compared with either agent alone. The patient population (n = 263) in this study was larger and the duration of
treatment (3 years) was longer than any of the DN studies
included in this meta-analysis. Additionally, this study demonstrated improvement in an accepted clinical end point, doubling of serum creatinine or progression to end-stage renal
disease, instead of proteinuria. While COOPERATE provides
strong evidence for dual RAAS blockade in non-diabetic nephropathy, our meta-analysis highlights the need for more study
of this strategy in DN.
This analysis is limited by the quality of the studies available
for inclusion. Studies included in this analysis were relatively
small, heterogeneous in design, patient population and intervention, short in duration and only evaluated albumin/protein
excretion, instead of more definitive clinical end points (doubling of serum creatinine, rate of end-stage renal disease or
mortality). In order to deal with some of these limitations, subgroup analysis was performed to address clinical heterogeneity
and the effect of combination therapy on GFR was assessed to
provide more information than simply effect on albumin/
protein excretion. Although these measures are not ideal for
eliminating the influence of the primary studies’ limitations,
they do help to clarify the issue and enable hypotheses to be
generated.
Only one of the studies included in this analysis was greater
than 12 weeks [25]. This study was 12 months in duration and
demonstrated no difference between combination therapy and
ACEI alone (P = 0.798). The CALM II study was also 12 months
in duration and demonstrated no difference in urinary albuminto-creatinine ratio (Table 1) [29]. CALM II was not included
in this meta-analysis because urinary albumin excretion was
not reported; however, these two studies together seem to
suggest that the early beneficial effect of combination therapy
on protein excretion may not translate into long-term benefit.
It should also be noted that our meta-analysis demonstrated
a reduction in blood pressure with combination therapy. The
majority of the studies included in this analysis not only
showed an improvement in both proteinuria and blood
pressure, but they also demonstrated statistically significant
correlations between these two parameters. Numerous studies
examining monotherapy with an ACEI or an ARB have shown
significant renoprotective effects of these medications independent of changes in blood pressure [4 –7,9–11]. However, a
recent meta-analysis of these studies reported a strong relationship between blood pressure reduction and reduction
in proteinuria [33]. The subgroup analysis of blood pressure
tertiles in this paper was an attempt to address the issue of
whether blood pressure reduction may be the major factor in
slowing the progression of renal dysfunction with combination therapy. Although a meta-analysis is not the optimal
method for clarifying this issue, this subgroup analysis suggests that additive blood pressure reduction cannot be dis-
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counted as playing a role in reducing albumin/protein excretion
with combination therapy. Future studies comparing dual
blockade to an ACEI combined with other anti-hypertensive
agents targeting similar blood pressure levels will have to be
conducted in order to fully address this issue.
Another important issue relates to the variability of the
baseline level of protein excretion in the studies included in the
analysis. In the overall analysis, data from studies enrolling
patients with microalbuminuria were combined with studies
including patients with macroalbuminuria or nephrotic range
proteinuria. This introduction of clinical heterogeneity was
addressed by determining per cent reduction in protein excretion and by analysing subgroups divided by tertiles of baseline
level of proteinuria. It appeared that those with the greatest
degree of proteinuria derive the greatest benefit from combination therapy. When baseline level of proteinuria was smaller,
there was no benefit with combination therapy. This is consistent
with the CALM study, as no benefit was observed with combination therapy in a microalbuminuric patient population
[15].
A final issue stems from the variety of medications and doses
employed in the studies included in our analysis (Table 1). The
majority of the studies included in this meta-analysis involved
the addition of an ARB to submaximal doses of an ACEI. Further, the optimal anti-proteinuric dose for ACE inhibitors and
the ARBs has never been established. However, recent studies
have demonstrated that higher doses of ACEI or ARB are superior
to lower doses for reducing proteinuria [11,34]. Therefore, it is
unclear from this analysis whether combination therapy would
be beneficial if an ARB was added to a maximal dose of an ACEI.
Future trials will first need to clarify the optimal anti-proteinuric
doses for both ACE inhibitors and ARBs, and then study these
optimal doses in mono- vs. combination therapy for DN.
In conclusion, our meta-analysis suggests that patients with
diabetic nephropathy derive short-term benefit from combination ACEI/ARB therapy. Given the limitations of the current
body of literature in this area, it is unclear whether short-term
beneficial effects on protein excretion persist with long-term
therapy or will translate to significant improvements in other
important end points. Future studies, evaluating accepted
clinical end points (doubling of serum creatinine, onset of
end-stage renal disease) are needed to establish the long-term
benefit of this treatment, as well as to define the optimal dose
of each agent and test the optimal doses of monotherapy against
dual RAAS blockade.
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